Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Approximately 50% of acute myeloid leukemia (AML) patients do not respond to induction therapy (primary induction failure [PIF]) or relapse after <6 months (early relapse [ER]). We have recently shown an association between an immune-infiltrated tumor microenvironment (TME) and resistance to cytarabine-based chemotherapy but responsiveness to flotetuzumab, a bispecific DART antibody-based molecule to CD3ε and CD123. This paper reports the results of a multicenter, open-label, phase 1/2 study of flotetuzumab in 88 adults with relapsed/refractory AML: 42 in a dose-finding segment and 46 at the recommended phase 2 dose (RP2D) of 500 ng/kg per day. The most frequent adverse events were infusion-related reactions (IRRs)/cytokine release syndrome (CRS), largely grade 1-2. Stepwise dosing during week 1, pretreatment dexamethasone, prompt use of tocilizumab, and temporary dose reductions/interruptions successfully prevented severe IRR/CRS. Clinical benefit accrued to PIF/ER patients showing an immune-infiltrated TME. Among 30 PIF/ER patients treated at the RP2D, the complete remission (CR)/CR with partial hematological recovery (CRh) rate was 26.7%, with an overall response rate (CR/CRh/CR with incomplete hematological recovery) of 30.0%. In PIF/ER patients who achieved CR/CRh, median overall survival was 10.2 months (range, 1.87-27.27), with 6- and 12-month survival rates of 75% (95% confidence interval [CI], 0.450-1.05) and 50% (95% CI, 0.154-0.846). Bone marrow transcriptomic analysis showed that a parsimonious 10-gene signature predicted CRs to flotetuzumab (area under the receiver operating characteristic curve = 0.904 vs 0.672 for the European LeukemiaNet classifier). Flotetuzumab represents an innovative experimental approach associated with acceptable safety and encouraging evidence of activity in PIF/ER patients. This trial was registered at www.clinicaltrials.gov as #NCT02152956.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2017) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,775
Self-citationChimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Metsalu, T., & Vilo, J. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv468 · Cited by 3,709
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Döhner, H., Weisdorf, D. J., & Bloomfield, C. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1406184 · Cited by 3,306
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Doehner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,654
Self-citationBlinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Kantarjian, H., Stein, A., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J.-M., Wei, A., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,143
Self-citationCreutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137
Teachey, D. T., Rheingold, S. R., Maude, S. L., Zugmaier, G., Barrett, D. M., Seif, A. E., Nichols, K. E., Suppa, E. K., Kalos, M., Berg, R. A., et al. (2013) · Blood · doi:10.1182/blood-2013-02-485623 · Cited by 613
Cited by
Döhner, H., Wei, A. H., Appelbaum, F. R., Craddock, C., DiNardo, C. D., Dombret, H., Ebert, B. L., Fenaux, P., Godley, L. A., Hasserjian, R. P., et al. (2022) · Blood · doi:10.1182/blood.2022016867 · Cited by 3,279
Self-citationAcute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management
Shimony, S., Stahl, M., & Stone, R. M. (2023) · American Journal of Hematology · doi:10.1002/ajh.26822 · Cited by 448
DiNardo, C. D., Erba, H. P., Freeman, S. D., & Wei, A. H. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00108-3 · Cited by 437
Self-citationTowards precision medicine for AML
Döhner, H., Wei, A. H., & Löwenberg, B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00509-w · Cited by 301
Self-citationEmerging agents and regimens for AML
Liu, H. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01062-w · Cited by 289
Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
Tian, Z., Liu, M., Zhang, Y., & Wang, X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01084-4 · Cited by 282
CAR-T cell therapy for cancer: current challenges and future directions
Zugasti, I., Espinosa-Aroca, L., Fidyt, K., Mulens-Arias, V., Diaz-Beya, M., Juan, M., Urbano-Ispizua, Á., Esteve, J., Velasco-Hernandez, T., & Menéndez, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02269-w · Cited by 281
Philipp, N., Kazerani, M., Nicholls, A., Vick, B., Wulf, J., Straub, T., Scheurer, M., Muth, A., Hänel, G., Nixdorf, D., et al. (2022) · Blood · doi:10.1182/blood.2022015956 · Cited by 280
Recent advances in targeted therapies in acute myeloid leukemia
Bhansali, R. S., Pratz, K. W., & Lai, C. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01424-6 · Cited by 275
T-cell-engaging bispecific antibodies in cancer
van de Donk, N. W. C. J., & Zweegman, S. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00521-4 · Cited by 267
Metadata
- Authors
- Uy, G. L., Aldoss, I., Foster, M. C., Sayre, P. H., Wieduwilt, M. J., Advani, A. S., Godwin, J. E., Arellano, M. L., Sweet, K. L., Emadi, A., Ravandi, F., Erba, H. P., Byrne, M., Michaelis, L., Topp, M. S., Vey, N., Ciceri, F., Carrabba, M. G., Paolini, S., Huls, G. A., Jongen-Lavrencic, M., Wermke, M., Chevallier, P., Gyan, E., Récher, C., Stiff, P. J., Pettit, K. M., Löwenberg, B., Church, S. E., Anderson, E., Vadakekolathu, J., Santaguida, M., Rettig, M. P., Muth, J., Curtis, T., Fehr, E., Guo, K., Zhao, J., Bakkacha, O., Jacobs, K., Tran, K., Kaminker, P., Kostova, M., Bonvini, E., Walter, R. B., Davidson-Moncada, J. K., Rutella, S., & DiPersio, J. F.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2021-02-11
- Volume
- 137
- Issue
- 6
- Pages
- 751-762
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W3085208365
- Cited by
- 326
- References
- 34
- FWCI
- 26.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.